1. Trang chủ
  2. » Giáo án - Bài giảng

Synthesis, anticandidal activity, and cytotoxicity of some thiazole derivatives with dithiocarbamate side chains

10 10 0

Đang tải... (xem toàn văn)

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 10
Dung lượng 178,44 KB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

Some thiazole derivatives bearing dithiocarbamic acid esters were synthesized in order to investigate their anticandidal activity and cytotoxicity. The structures of the obtained final compounds (6a–j) were confirmed by spectral data (IR, 1H NMR, 13C NMR, and MS) and elemental analysis. The anticandidal activity of the compounds was determined (6a–j) using the microbroth dilution method and their cytotoxicity was evaluated according to the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay against normal cells. Contrary to expectations, weak antifungal activity was observed with IC50 values ranging between 30 and 403 µg/mL.

Trang 1

⃝ T¨UB˙ITAK

doi:10.3906/kim-1312-62

h t t p : / / j o u r n a l s t u b i t a k g o v t r / c h e m /

Research Article

Synthesis, anticandidal activity, and cytotoxicity of some thiazole derivatives with

dithiocarbamate side chains

Leyla YURTTAS ¸1, ∗, Yusuf ¨ OZKAY1, Fatih DEM˙IRC˙I2, Gamze G ¨ OGER2,

S ¸afak ULUSOYLAR YILDIRIM3, Usama ABU MOHSEN4, ¨ Omer ¨ OZT ¨ URK1,

Zafer Asım KAPLANCIKLI1,5

1

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eski¸sehir, Turkey

2

Department of Pharmacognosy, Faculty of Pharmacy, Anadolu University, Eski¸sehir, Turkey

3

Department of Pharmacology, Faculty of Pharmacy, Anadolu University, Eski¸sehir, Turkey

4

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Gaza, Palestine

5Department of Pharmaceutical Chemistry, Graduate School of Health Sciences, Anadolu University,

Eski¸sehir, Turkey

Received: 26.12.2013 Accepted: 26.03.2014 Published Online: 15.08.2014 Printed: 12.09.2014

Abstract: Some thiazole derivatives bearing dithiocarbamic acid esters were synthesized in order to investigate their anticandidal activity and cytotoxicity The structures of the obtained final compounds (6a–j) were confirmed by spectral

data (IR, 1H NMR, 13C NMR, and MS) and elemental analysis The anticandidal activity of the compounds was

determined (6a–j) using the microbroth dilution method and their cytotoxicity was evaluated according to the MTT

(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay against normal cells Contrary to expectations, weak antifungal activity was observed with IC50 values ranging between 30 and 403 µ g/mL.

Key words: Thiazole, dithiocarbamate, anticandidal activity, cytotoxicity

1 Introduction

Candidiasis encompasses infections that range from superficial, such as oral thrush and vaginitis, to systemic and potentially life-threatening diseases particularly in patients undergoing anticancer chemotherapy, organ transplants, or long treatment with antimicrobial agents and in patients with AIDS because of immune system suppression Such a broad range of infections and development of resistance to currently available antifungal

which are an important class of sulfur-containing compounds, were also described as herbicides and fungicides,

last decade, dithiocarbamate moiety combined with different heterocyclic ring systems was studied widely,

compounds are known to act as inhibitors of enzymes and have a profound effect on biological systems, because

of their strong metal-binding capacity The well-known thiocarbamate class of antifungal drug tolciclate (I) and the fungicidal active plant defense agent brassinin (II) are famous sulfurated compounds Additionally,

Correspondence: lyurttas@anadolu.edu.tr

Trang 2

rhodanine (III) and its derivatives are the other dithiocarbamate-including molecules known for their ability to

inhibit fungal protein mannosyl transferase 1 (PMT1), which plays a key role in the biosynthesis of the fungal

Figure The chemical structures of the tolciclate (I), brassinin (II), and rhodanine (III).

Thiazoles have a prominent position among heterocycles and they can be obtained from microbial and

(anti-neoplastic agents), ritonavir (anti-HIV drug), fanetizole and meloxicam (anti-inflammatory agents), nizatidine

peni-cillin (antibiotic) Besides these bioactive compounds, there are a lot of studies about thiazole derivatives with

According to the foregoing literature survey, we now report the synthesis of the dithiocarbamic acid

derivatives of N -[4-(2-methyl-4-thiazolyl)phenyl]acetamide structure with potential anticandidal activity and

cytotoxicity in this study

2 Results and discussion

The present study was undertaken to synthesize some thiazole derivatives bearing dithiocarbamic acid ester and

to investigate their anticandidal activity and cytotoxicity The target compounds were obtained in multistep organic synthesis as shown in the Scheme The initial compound 4-aminoacetophenone in a TEA/THF mixture

was acetylated with chloroacetyl chloride to obtain 4-(acetylamino)acetophenone (1); then compound 1 in AcOH

was brominated to obtain N -[4-(2-bromoacetyl)phenyl]acetamide (2) The obtained amide compound (2) was reacted with thioacetamide to give N -[4-(2-methyl-4-thiazolyl)phenyl]acetamide (3) After hydrolysis of the

acetyl group on amino moiety, compound 4-(2-methyl-4-thiazolyl)aniline (4) was synthesized, which was then

acetylated with chloroacetyl chloride to obtain 2-chloro- N -[4-(2-methyl-4-thiazolyl)phenyl]acetamide (5) In

the final step, compound 5 was reacted with appropriate dithiocarbamate salts to give the final compounds (6a–6j) Compound 6c (2-[[4-(2-methyl-4-thiazolyl)phenyl]amino]-2-oxoethyl morpholine-4-carbodithioate) was

synthesized and registered with the chemical abstract service before, but there are no scientific data about the molecule and so we included this compound in our research

The structures of the synthesized compounds were elucidated by spectral data and elemental analysis, and significant stretching bands in the IR spectra were observed in the expected regions Stretching bands

NMR spectra of the compounds, methyl protons at the second position of the thiazole ring and N–H protons

Trang 3

Scheme The synthesis of the compounds (6a–j) Reagents: (i) acetyl chloride, TEA, THF, 0–5 C; (ii) Br2, AcOH; (iii) thioacetamide, EtOH, r.t (iv) 10% HCl, EtOH, reflux; (v) chloroacetyl chloride, TEA, THF, r.t.; (vi) appropriate

sodium salts of N, N -disubstituted dithiocarbamic acids, K2CO3, acetone, reflux

the thiazole ring was observed at about 7.23–7.27 ppm and as 2 singlets that are thought to be due to magnetic

ppm as singlets and protons of the cyclic structures were seen at 1.73 ppm and 4.65 ppm as broad singlets,

Trang 4

commonly The other peaks belonging to aromatic and aliphatic protons were observed in the estimated areas.

peaks at 191–197 ppm C=N carbons of the thiazole ring were recorded at 156–157 ppm The mass spectra (EI-MS) of the compounds showed (M+1) peaks in agreement with their molecular weight Elemental analysis results for C, H, and N elements were satisfactory within calculated values of the compounds

The target compounds 6a–j were screened for their in vitro anticandidal activity against 7 candida

species, including standard strains and clinical isolates MIC is defined as the concentration of the compound required to give complete inhibition of bacterial growth and MICs of the synthesized compounds along with the reference drug ketoconazole are given The results provided in Table 1 indicate that most of the prepared

compounds displayed broad antifungal spectra with MIC values ranging from 62.5 to 125 µ g/mL against all the

tested strains Among all evaluated strains, the compounds 6a, 6b, 6c, 6f, and 6g had anticandidal activity

lower than that of the standard drug Compound 6a inhibited all species at a concentration of 62.5 µ g/mL except against C tropicalis Both of the compounds 6b and 6c displayed anticandidal activity against C.

albicans (ATCC 90028) and C glabrata (isolate 1) at the same concentrations (62.5 µ g/mL) Compounds were

against NIH/3T3 cells are shown in Table 2 The biological study indicated that compound 6f possessed the

highest cytotoxicity, with a value of about 30 µ g/mL, whereas compound 6i exhibited the lowest cytotoxicity,

with a value of about 330 µ g/mL, against NIH/3T3 cells.

Table 1 Anticandidal activity of the compounds (MIC in µ g/mL).

6a 62.5 62.5 62.5 125 62.5 62.5 62.5

6b 125 62.5 62.5 125 125 62.5 125

6c 62.5 62.5 125 125 125 62.5 125

6f 125 125 125 62.5 62.5 125 62.5

6g 62.5 125 125 125 125 62.5 62.5

Ref.: Ketoconazole, ND: Not defined

A: C albicans (isolate, obtained from Department of Microbiology, Faculty of Medicine, Osmangazi University, Eski¸sehir, Turkey), B: C glabrata (isolate 1, obtained from Department of Microbiology, Faculty of Medicine, Osmangazi University, Eski¸sehir, Turkey), C: C utilis (NRRLY-900), D: C tropicalis (NRRLY-12968), E: C krusei (NRRLY-7179), F: C albicans (ATCC 90028), G: C glabrata (isolate 2, obtained from Department of Microbiology, Faculty of Medicine,

Osmangazi University, Eski¸sehir, Turkey)

3 Conclusion

In this study, we report the synthesis, spectral studies, and biological evaluation of some thiazole derivatives

bearing dithiocarbamic acid ester (6a–j) The structures proposed for the synthesized compounds (6a–j) are

Trang 5

well supported by spectroscopic data and elemental analysis Some of the final compounds (6a, 6b, 6c, 6f, and 6g) were evaluated for their anticandidal activity and they exhibited weak activity against all tested strains The cytotoxicity of the compounds was also studied and compounds 6c, 6d, 6h, and 6i displayed the lowest

cytotoxicity against NIH/3T3 cells

Table 2 In vitro cytotoxicity of the compounds.

aCytotoxicity of the compounds to mouse fibroblast (NIH/3T3) cell line Incubation for 24 h IC50 is the drug concentration required to inhibit 50% of the cell growth The values represent mean ± standard deviation of triplicate

determinations

4 Experimental

All chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA) All melting points (mps) were deter-mined by Electrothermal 9100 digital melting point apparatus (Electrothermal, Essex, UK) and are uncorrected All the reactions were monitored by thin-layer chromatography (TLC) using Silica Gel 60 F254 TLC plates (Merck KGaA, Darmstadt, Germany) Spectroscopic data were recorded with the following instruments: IR, Shimadzu 8400S spectrophotometer (Shimadzu, Tokyo, Japan); NMR, VARIAN Mercury 400 FT spectrometer

AB Sciex-3200 Q-TRAP LC/MS/MS system (Applied Biosystems Co., MA, USA)

4.1 4’-Acetaminoacetophenone (1)

4’-Aminoacetophenone (0.05 mol, 6.75 g) and triethylamine (0.06 mol, 8.34 mL) were dissolved in THF (100

solution The reaction mixture was stirred for 1 h at room temperature After evaporation of solvent, the

4.2 4-(2-Bromoacetyl)acetanilide (2)

Compound 1 (0.04 mol, 7.08 g) and HBr (0.5 mL) were dissolved in acetic acid (30 mL) and bromine (0.044

mol, 2.27 mL) was added dropwise at room temperature After completion of the addition of bromine, the reaction mixture was stirred for 1 h and then poured into ice-water (100 mL) The precipitated product was

Trang 6

185–187 C).22 IR: (KBr) ν max (cm−1) : 3363 (amide N–H), 3062 (aromatic C–H), 1698 (ketone C=O), 1665

(amide C=O), 1378–1196 (C–N), and 848 (1,4-disubstituted benzene)

4.3 4-(2-Methyl-4-thiazolyl)acetanilide (3)

Compound 2 (0.03 mol, 7.68 g) and thioacetamide (0.03 mol, 2.25 g) in ethanol (100 mL) were stirred at room

temperature for 48 h The precipitated product was filtered, dried, and recrystallized from ethanol Yield: 78%;

(amide C=O), 1367–1211 (C–N), and 843 (1,4-disubstituted benzene)

4.4 4-(2-Methyl-4-thiazolyl)aniline (4)

Compound 3 (0.025 mol, 5.8 g) was refluxed in 10% HCl (100 mL) for 1 h The mixture was cooled down,

(1,4-disubstituted benzene)

4.5 2-Chloro-N -[4-(2-methyl-4-thiazolyl)phenyl]acetamide (5)

Chloroacetyl chloride (0.02 mol, 1.6 mL) was added dropwise over 15 min to a magnetically stirred solution of

compound 4 (0.02 mol, 3.8 g) and triethylamine (0.02 mol, 2.8 mL) in dry THF (15 mL) After completion

of the reaction, the solvent was evaporated under reduced pressure Water was added to wash the resulting

solid and the mixture was filtered, dried, and recrystallized from ethanol to give compound 5 Yield: 83%; mp

(d, 2H, J = 8.1 Hz, Ar–H), and 10.50 (s, 1H, N–H).

4.6 General methods for synthesis of compounds 6a–j

Compound 5 (0.001 mol) was stirred with appropriate sodium salts of dithiocarbamic acids (0.0011 mol) in

acetone for 3 h The precipitated product was filtered and washed with water

4.6.1 2-[[4-(2-Methyl-4-thiazolyl)phenyl]amino]-2-oxoethyl diethylcarbamodithiodate (6a)

167.45, 194.90 MS (ES+): m/z 380

Trang 7

4.6.2 2-[[4-(2-Methyl-4-thiazolyl)phenyl]amino]-2-oxoethyl pyrrolidine-1-carbodithiodate (6b)

154.92, 166.00, 167.39, 191.87 MS (ES+): m/z 378

4.6.3 2-[[4-(2-Methyl-4-thiazolyl)phenyl]amino]-2-oxoethyl morpholine-4-carbodithioate (6c)

166.62, 196.471 MS (ES+): m/z 394

4.6.4 2-[[4-(2-Methyl-4-thiazolyl)phenyl]amino]-2-oxoethylthiomorpholine-4-carbodithioate (6d)

40.73, 54.01, 56.03, 111.85, 120.08, 127.10, 130.94, 137.88, 154.83, 166.05, 166.83, 196.02 MS (ES+): m/z 410

4.6.5 2-[[4-(2-Methyl-4-thiazolyl)phenyl]amino]-2-oxoethyl piperidine-1-carbodithioate (6e)

167.16, 194.41 MS (ES+): m/z 390

4.6.6 2-[[4-(2-Methyl-4-thiazolyl)phenyl]amino]-2-oxoethyl 4-methylpiperazine-1-carbodithioate (6f )

154.85, 166.07, 167.11, 196.02 MS (ES+): m/z 407

Trang 8

4.6.7 2-[[4-(2-Methyl-4-thiazolyl)phenyl]amino]-2-oxoethyl 4-ethyllpiperazine-1-carbodithioate (6g)

111.84, 120.11, 127.08, 130.84, 137.98, 154.86, 166.09, 167.15, 195.79 MS (ES+): m/z 421

4.6.8 2-[[4-(2-Methyl-4-thiazolyl)phenyl]amino]-2-oxoethyl 4-benzylpiperazine-1-carbodithioate (6h)

129.33, 130.86, 137.17, 137.77, 154.67, 165.79, 166.89, 195.61 MS (ES+): m/z 483

4.6.9 2-[[4-(2-Methyl-4-thiazolyl)phenyl]amino]-2-oxoethyl 4-(pyrimidin-2-yl)piperazine-1-carbo-dithioate (6i)

J = 4.8 Hz, 2H, Ar–H), 9.13 (s, 1H, N–H). 13C NMR (100 MHz, CDCl3) δ 19.32, 40.34, 42.94, 50.10, 52.16,

110.91, 111.58, 119.86, 126.86, 130.66, 137.70, 154.62, 157.84, 161.16, 165.81, 166.71, 196.27 MS (ES+): m/z 471

4.6.10 Bis{2-[[4-(2-methyl-4-thiazolyl)phenyl]amino]-2-oxoethyl}

piperazine-1,4-bis(carbodithio-ate) (6j)

139.32, 154.24, 165.89, 166.05, 195.60 MS (ES+): m/z 699

4.7 Anticandidal activity assay

Anticandidal activity of the final compounds was evaluated by the broth microdilution method according to the

Trang 9

were as follows: C albicans (isolate, obtained from Department of Microbiology, Faculty of Medicine, Osmangazi University, Eski¸sehir, Turkey), C glabrata (isolate 1, obtained from Department of Microbiology, Faculty of Medicine, Osmangazi University, Eski¸sehir, Turkey), C utilis (NRRLY-900), C tropicalis (NRRLY-12968), C.

krusei (NRRLY-7179), C albicans (ATCC 90028), and C glabrata (isolate 2, obtained from Department of

Microbiology, Faculty of Medicine, Osmangazi University, Eski¸sehir, Turkey) Ketoconazole was used as positive control and the results (MIC values) are shown in Table 1

4.8 Cytotoxicity assay

Cytotoxic properties of the compounds were determined by the method mentioned in the literature using mouse

2 The procedure was realized using the standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

per well) All the compounds were dissolved in DMSO individually and added to culture wells at varying

concentrations (0.5–500 µ g/mL); the highest final DMSO concentration was under 0.1% After 24 h of drug

a 3-h incubation period was maintained in the same conditions Purple formazan occurred at the end of the process, which is the reduction product of MTT agent by the mitochondrial dehydrogenase enzyme of intact cells Formazan crystals were dissolved in 100 mL of DMSO and the absorbance was read by ELISA reader (OD 570 nm) The percentage of viable cells was calculated based on the medium control

References

1 Secci, D.; Bizzarri, B.; Bolasco, A.; Carradori, S.; D’Ascenzio, M.; Rivanera, D.; Mari, E.; Polletta, L.; Zicari, A

Eur J Med Chem 2012, 53, 246–253.

2 Pappas, P G.; Rex, J H.; Sobel, J D.; Filler, S G.; Dismukes, W E.; Walsh, T J.; Edwards, J E Clin Infect.

Dis 2004, 38, 161–189.

3 Williams, J S.; Cooper, R M Plant Pathology 2004, 53, 263–279.

4 Kuhr, R J.; Dorough, H W Carbamate Insecticides: Chemistry, Biochemistry, and Toxicology ; CRC Press: Boca

Raton, FL, USA, 1976

5 Ozkırımli, S.; Apak, T ˙I.; Kiraz, M.; Yegenoglu, Y Arch Pharm Res 2005, 28, 1213–1218.¨

6 Monti, S M.; Maresca, A.; Viparelli, F.; Carta, F.; De Simone, G.; M¨uhlschlegel, F A.; Scozzafava, A.; Supuran,

C T Bioorg Med Chem Lett 2012, 22, 859–862.

7 Miller, C R.; Elson, W J Bacteriol 1949, 57, 47–54.

8 Kligman, A M.; Rosensweig, W J Investigative Dermatol 1948, 10, 59–68.

9 Karaburun, A C¸ ; Kaplancıklı, Z A.; G¨undo˘gdu-Karaburun, N.; Demirci, F Lett Drug Des Discov 2011, 8,

811–815

10 Chauhan, K.; Sharma, M.; Singh, P.; Kumar, V.; Shukla, P K.; Siddiqi, M I.; Chauhan, P M S Med Chem.

Comm 2012, 3, 1104–1110.

11 Pedras, M S C.; Khan, A Q.; Smith, K C.; Stettner, S L.; Can J Chem 1997, 75, 825–828.

12 Hodgetts, K J.; Kershaw, M T Org Lett 2002, 4, 1363–1365.

13 Mohanty, D Curr Pharm Res 2012, 3, 750–763.

14 Siddiqui, N.; Arshad, M F.; Ahsan, W.; Alam, M S Int J Pharm Sci Drug Res 2009, 1, 136–143.

Trang 10

15 Bharti S K.; Nath, G.; Tilak, R.; Singh, S K Eur J Med Chem 2010, 45, 651–660.

16 Clough, J M.; Dube, H.; Martin, B J.; Pattenden, G.; Reddy, K S.; Waldron, I R Org Biomol Chem 2006, 4,

2906–2911

17 B¨ohlendorf, B.; Herrmann, M.; Hecht, H.; Sasse, F.; Forche, E.; Kunze, B.; Reichenbach, H.; H¨ofle, G Eur J Org.

Chem 1999, 10, 2601–2608.

18 Al-Saadi, M S.; Faidallah, H M.; Rostom, S A F Arch Pharm Chem Life Sci 2008, 341, 424–434.

19 Narayana, B.; Raj, K K V.; Ashalatha, B V.; Kumari, N S.; Sarojini B K Eur J Med Chem 2004, 39,

867–872

20 Karegoudar, P.; Karthikeyan, M S.; Prasad, D J.; Mahalinga, M.; Holla, B S.; Kumari, N S Eur J Med Chem.

2008, 43, 261–267.

21 Peet, N P.; Sunder, S.; Barbuch, R J.; Whalon, M R.; Huber, E W.; Huffman, J C J Het Chem 1989, 26,

1611–1617

22 Xing, R.; Pan, L.; Wen, X J Chinese Pharm Sci 2010, 19, 400–402.

23 Yurchenko, R I.; Malitskaya, V P Zh Org Khim 1977, 13, 1980–1987.

24 Yurtta¸s, L.; ¨Ozkay, Y.; Akalın-Ciftci, G.; Ulusoylar-Yıldırım, S¸ J Enzyme Inhib Med Chem 2014, 29, 175–184.

25 Kaplancikli, Z A.; Yurtta¸s, L.; ¨Ozdemir, A.; Turan-Zitouni, G.; Iscan, G.; Akalın, G.; Abu Mohsen, U J Enzym.

Inhib Med Chem 2014, 29, 43–48.

26 Mossmann, T J Immunol Methods 1983, 65, 55–63.

Ngày đăng: 12/01/2022, 23:18

Nguồn tham khảo

Tài liệu tham khảo Loại Chi tiết
1. Secci, D.; Bizzarri, B.; Bolasco, A.; Carradori, S.; D’Ascenzio, M.; Rivanera, D.; Mari, E.; Polletta, L.; Zicari, A.Eur. J. Med. Chem. 2012, 53, 246–253 Sách, tạp chí
Tiêu đề: Eur. J. Med. Chem."2012,"53
2. Pappas, P. G.; Rex, J. H.; Sobel, J. D.; Filler, S. G.; Dismukes, W. E.; Walsh, T. J.; Edwards, J. E. Clin. Infect.Dis. 2004, 38, 161–189 Sách, tạp chí
Tiêu đề: Clin. Infect."Dis."2004,"38
3. Williams, J. S.; Cooper, R. M. Plant Pathology 2004, 53, 263–279 Sách, tạp chí
Tiêu đề: Plant Pathology" 2004,"53
4. Kuhr, R. J.; Dorough, H. W. Carbamate Insecticides: Chemistry, Biochemistry, and Toxicology; CRC Press: Boca Raton, FL, USA, 1976 Sách, tạp chí
Tiêu đề: Carbamate Insecticides: Chemistry, Biochemistry, and Toxicology
5. Ozkırımli, S.; Apak, T. ˙I.; Kiraz, M.; Yegenoglu, Y. ¨ Arch. Pharm. Res. 2005, 28, 1213–1218 Sách, tạp chí
Tiêu đề: Arch. Pharm. Res."2005,"28
6. Monti, S. M.; Maresca, A.; Viparelli, F.; Carta, F.; De Simone, G.; M¨ uhlschlegel, F. A.; Scozzafava, A.; Supuran, C. T. Bioorg. Med. Chem. Lett. 2012, 22, 859–862 Sách, tạp chí
Tiêu đề: Bioorg. Med. Chem. Lett."2012,"22
7. Miller, C. R.; Elson, W. J. Bacteriol. 1949, 57, 47–54 Sách, tạp chí
Tiêu đề: J. Bacteriol."1949,"57
8. Kligman, A. M.; Rosensweig, W. J. Investigative Dermatol. 1948, 10, 59–68 Sách, tạp chí
Tiêu đề: J. Investigative Dermatol."1948,"10
9. Karaburun, A. C á .; Kaplancıklı, Z. A.; Gă undo˘ gdu-Karaburun, N.; Demirci, F. Lett. Drug Des. Discov. 2011, 8, 811–815 Sách, tạp chí
Tiêu đề: Lett. Drug Des. Discov."2011, "8
10. Chauhan, K.; Sharma, M.; Singh, P.; Kumar, V.; Shukla, P. K.; Siddiqi, M. I.; Chauhan, P. M. S. Med. Chem.Comm. 2012, 3, 1104–1110 Sách, tạp chí
Tiêu đề: Med. Chem."Comm."2012,"3
11. Pedras, M. S. C.; Khan, A. Q.; Smith, K. C.; Stettner, S. L.; Can. J. Chem. 1997, 75, 825–828 Sách, tạp chí
Tiêu đề: Can. J. Chem."1997,"75
12. Hodgetts, K. J.; Kershaw, M. T. Org. Lett. 2002, 4, 1363–1365 Sách, tạp chí
Tiêu đề: Org. Lett."2002,"4
14. Siddiqui, N.; Arshad, M. F.; Ahsan, W.; Alam, M. S. Int. J. Pharm. Sci. Drug Res. 2009, 1, 136–143 Sách, tạp chí
Tiêu đề: Int. J. Pharm. Sci. Drug Res."2009,"1
15. Bharti S. K.; Nath, G.; Tilak, R.; Singh, S. K. Eur. J. Med. Chem. 2010, 45, 651–660 Sách, tạp chí
Tiêu đề: Eur. J. Med. Chem."2010,"45
16. Clough, J. M.; Dube, H.; Martin, B. J.; Pattenden, G.; Reddy, K. S.; Waldron, I. R. Org. Biomol. Chem. 2006, 4, 2906–2911 Sách, tạp chí
Tiêu đề: Org. Biomol. Chem."2006,"4
17. B¨ ohlendorf, B.; Herrmann, M.; Hecht, H.; Sasse, F.; Forche, E.; Kunze, B.; Reichenbach, H.; H¨ ofle, G. Eur. J. Org.Chem. 1999, 10, 2601–2608 Sách, tạp chí
Tiêu đề: Eur. J. Org."Chem."1999,"10
18. Al-Saadi, M. S.; Faidallah, H. M.; Rostom, S. A. F. Arch. Pharm. Chem. Life Sci. 2008, 341, 424–434 Sách, tạp chí
Tiêu đề: Arch. Pharm. Chem. Life Sci."2008,"341
19. Narayana, B.; Raj, K. K. V.; Ashalatha, B. V.; Kumari, N. S.; Sarojini B. K. Eur. J. Med. Chem. 2004, 39, 867–872 Sách, tạp chí
Tiêu đề: Eur. J. Med. Chem." 2004, "39
20. Karegoudar, P.; Karthikeyan, M. S.; Prasad, D. J.; Mahalinga, M.; Holla, B. S.; Kumari, N. S. Eur. J. Med. Chem.2008, 43, 261–267 Sách, tạp chí
Tiêu đề: Eur. J. Med. Chem."2008,"43
21. Peet, N. P.; Sunder, S.; Barbuch, R. J.; Whalon, M. R.; Huber, E. W.; Huffman, J. C. J. Het. Chem. 1989, 26, 1611–1617 Sách, tạp chí
Tiêu đề: J. Het. Chem." 1989,"26

TỪ KHÓA LIÊN QUAN

TÀI LIỆU CÙNG NGƯỜI DÙNG

TÀI LIỆU LIÊN QUAN

🧩 Sản phẩm bạn có thể quan tâm